(MedPage Today) — Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed.
Forced vital capacity (FVC) declined from baseline…
Source link : https://www.medpagetoday.com/meetingcoverage/ats/115633
Author :
Publish date : 2025-05-18 21:15:00
Copyright for syndicated content belongs to the linked Source.
